Showing results (81-90 of 731) with videos related to
Sort By:
Pageof 74
Diseases (Basel, Switzerland)|January 3, 2018
Risk Evaluation Requires an Independent MindChristian Schmidt, Joachim StorsbergHaematologica|June 1, 2005
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent eventsGerhard Herzog, Juxian Lu-Hesselmann, Yvonne Zimmermann, et al.The Cochrane Database of Systematic Reviews|September 14, 2012
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaLiat Vidal, Anat Gafter-Gvili, Ronit Gurion, et al.Histopathology|March 16, 2011
Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeMi Kyung Jin, Eva Hoster, Martin Dreyling, et al.Leukemia & Lymphoma|August 4, 2015
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathwayAnna-Katharina Zoellner, Stephan Bayerl, Grit Hutter, et al.European Journal of Haematology|April 5, 2018
Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell linesAnna-Katharina Zoellner, Nico Peter, Yvonne Zimmermann, et al.Leukemia & Lymphoma|February 1, 2017
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshopBrad S Kahl, Martin Dreyling, Leo I Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.Leukemia & Lymphoma|May 7, 2015
Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium WorkshopBrad S Kahl, Leo I Gordon, Martin Dreyling, et al.European Journal of Haematology|June 11, 2014
Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literatureStefan K Alig, Martin Dreyling, Bettina Seppi, et al.Pageof 74